

ANNUAL REVIEW OF CHRONOPHARMACOLOGY

Volume 1

BIOLOGICAL RHYTHMS AND MEDICATIONS

*Proceedings of the First Montreux Conference of
Chronopharmacology, Montreux, 26–30 March 1984*

Editors:

A. REINBERG

Fondation A. de Rothschild, Paris, France

M. SMOLENSKY

University of Texas, Houston, U.S.A.

G. LABRECQUE

Université de Laval, Québec, Canada



PERGAMON PRESS

OXFORD · NEW YORK · TORONTO · SYDNEY · PARIS · FRANKFURT

CONTENTS

Section 1 — Neurobiology

Chairmen: A. WIRZ-JUSTICE (Basel, Switzerland)
W. RIETVELD (Leiden, Netherland)

The effect of partial lesions of the hypothalamic suprachiasmatic nucleus on the circadian control of behaviour	1
W. J. RIETVELD	
<i>In vivo</i> voltammetry: monitoring drug induced changes in 5HT at the suprachiasmatic nucleus level	5
K. F. MARTIN and C. A. MARSDEN	
Effect of prolonged administration of clomipramine on 24-hour variation in 5HT metabolism in the rat brain	9
K. F. MARTIN and P. H. REDFERN	
Chronopharmacological alterations in pentobarbital induced hypnosis and body temperature produced by drugs influencing brain monoamines	13
S. G. SPECIALE and A. H. FRIEDMAN	
Circadian dysrhythmias in the EEG of children with clonazepam treatment	17
B. ARBOGAST, M. HALLEK, H. ARBOGAST, T. HELLBRÜGGE and R. SCHMID	
Temporal and sex related variations of lorazepam kinetics	21
B. BRUGUEROLLE, G. BOUVENOT and R. BARTOLIN	
Effects of different treatments on the circadian rhythm of plasma prolactin in Parkinson's disease	25
E. FERRARI, G. MICIELI, P. A. BOSSOLO, E. MARTIGNONI, L. MAGNANI and G. NAPPI	

Circadian rhythms in the waking EEG A. GUNDEL	29
Circadian patterns of plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) in normal and depressed subjects A. HALARIS	33
Circadian dysrhythmia in the behavior of epileptic children with clonazepam and/or phenobarbital treatment M. HALLEK, B. ARBOGAST, T. HELLBRÜGGE, R. SCHMID, H. ARBOGAST and B. KLEISER	37
Quantitative chronopharmacodynamic endpoint in health and schizophrenia: timing of plasma dehydroepiandrosterone (DHEA) versus DHEA-sulfate B. KLEISER, F. HALBERG, G. CORNELISSEN and C. VAN VALKENBURG	41
Effect of benztropine on plasma haloperidol chronopharmacology and blood choline levels in man R. S. NATHAN, J. M. PEREL, I. HANIN, U. KOPP, T. McCARTHY and R. STILLER	45
A comparison of three-time-daily and single dose regime of haloperidol R. LUND and E. RÜTHER	49
Gamma-aminobutyric acid and the neural basis of circadian timekeeping: implications for pathophysiology and psychopharmacotherapy of circadian based disorders D. BORSOOK, M. C. MOORE-EDE, T. HEDBERG, G. RICHARDSON and M. J. W. BRENNAN	53
 Section 2 — Antihistamines & Bronchodilators	
<i>Chairmen:</i> M. SMOLENSKY (Houston, Texas, U.S.A.) A. REINBERG (Paris, France)	
Antihistamine and other effects of 5 mg mequitazine vary between morning and evening acute administration A. REINBERG, F. LÉVI, J. P. FOURTILLAN, C. PEIFFER, A. BICAKOVA-ROCHER and A. NICOLAI	57

Biologic time related changes in anti-histamine and other effects of chronic administration of mequitazine in healthy adults	61
A. REINBERG, F. LÉVI, A. BICAKOVA-ROCHER, J. P. BLUM, M. M. OUECHNI and A. NICOLAI	
Multicentric chronotherapeutic study of mequitazine in patients with allergic rhinitis	65
P. GERVAIS	
Comparison of nocturnal and diurnal theophylline levels at steady-state	69
S. SAMAN, R. FOX, S. BUKANTZ and R. LOCKEY	
Chronopharmacology of theophylline, with special reference to age	73
J. H. G. JONKMAN and M. H. SMOLENSKY	
Circadian rhythms in steady-state theophylline pharmacokinetics in children	77
W. G. KRAMER, P. H. SCOTT, M. H. SMOLENSKY, R. HARRIST, P. HIATT, J. BAENZIGER, B. KLANK and H. EIGEN	
Circadian variation in theophylline absorption	81
M. St. PEIRRE, S. LEEDER, M. SPINO, A. ISLES and S. MacLEOD	
Variation in theophylline levels following morning or evening administration	85
W. R. PRIMROSE	
The effect of sustained-release theophylline on the circadian variation of pulmonary function in pediatric asthmatic patients	89
P. SCOTT, R. HARRIST, M. SMOLENSKY, W. KRAMER, P. HIATT, J. BAENZIGER, B. KLANK and H. EIGEN	
A chronopharmacokinetic model for controlled-release formulations	93
A. STRAUGHN, M. MEYER, A. GOLUB and M. GONZALEZ	
Chronopharmacokinetics of caffeine in healthy volunteers	97
M. LEVY, L. GRANIT and E. ZYLBER-KATZ	
Slow release terbutaline in nocturnal bronchial obstruction: relation of terbutaline dosage and blood levels with circadian changes in peak flow values	101
D. S. POSTMA, G. H. KOËTER, H. MEURS and J. J. KEYZER	

- Nocturnal bronchial obstruction: influence of slow release
terbutaline on circadian rhythm of spirometry, histamine
and catecholamines 105
D. S. POSTMA, G. H. KOËTER, H. MEURS and J. J. KEYZER

Section 3 — Anticancerous Medications & Cancer

Chairmen: L. E. SCHEVING (Little Rock, Arkansas,
U.S.A.)
E. HAUS (Saint-Paul, Minn., U.S.A.)

- Meal scheduling, fasting, cellular rhythms and
chronotherapy of cancer 109
L. A. SCHEVING, T. H. TSAI, L. E. SCHEVING
and J. E. PAULY

- Circadian variation in serum concentration of
carcinoembryonic antigen (CEA) is altered in cancer patients 111
C. FOCAN, V. CASTRONOVO, J. COLLETTE, D. FOCAN-
HENRARD, M. H. FRÈRE, S. LE HUNG, Y. TOUITOU and
P. FRANCHIMONT

- Circadian rhythm in cisplatin binding on plasma proteins 115
B. HECQUET, J. MEYNADIER, J. BONNETERRE and
L. ADENIS

- Circadian chronopharmacokinetics and chronotoxicology of
doxorubicin and cisplatin in human beings with cancer 119
W. J. M. HRUSHESKY

- Protein synthesis in human tumor cell populations —
governed by periodically transferred signals 123
T. LEDERER, A. LEHMER and K. ZÄNKER

- Chronopharmacology: a critical stage in the development of
anticancer drugs? THP adriamycin as an example 127
F. LÉVI, J. P. BLUM, G. LEMAIGRE, M. MECHKOURI,
A. ROULON, A. REINBERG and G. MATHÉ

- Circadian rhythms in 6 circulating lymphocyte subtypes in
healthy men: a 100-fold variation may be physiologic 131
F. LÉVI, C. CANON, J. P. BLUM, J. L. MISSET,
M. MECHKOURI, M. BENNACEUR and G. MATHÉ

- Multifrequency chronotherapy with circaseptan and
eventually circannual optimization may follow early
circadian-sinusoidal pump-implemented infusions of
cyclosporine 133
T. LIU, M. CAVALLINI, F. HALBERG, G. CORNELISSEN,
J. FIELD and D. E. R. SUTHERLAND

Chronobiology of urate excretion after cytostatic treatment M. H. ROBINSON, M. S. KNAPP and R. POWNALL	137
Plasma carcinoembryonic antigen rhythm in patients with ovarian cancer: effects of chemotherapy Y. TOUITOU, W. HRUSHESKY, C. FOCAN, A. AUZÉBY and A. BOGDAN	141
Effect of corticosteroids and melatonin on the circadian rhythm of methotrexate toxicity in the rat J. ENGLISH, G. W. AHERNE and J. ARENDT	145
The effect of circadian rhythm on immune function and splenic lymphocyte subset ratios in mice G. FERNANDES, N. TALAL and J. DE HAVEN	149
Section 4 — Statistics, Methods and Instrumentation (Including Pumps)	
<i>Chairmen:</i> J. De PRINS (Brussels, Belgium) W. HRUSHESKY (Minneapolis, Minn., U.S.A.)	
Serial section with flexible period correction and an application in longterm EEG analysis B. ARBOGAST and TH. HELLBRÜGGE	153
Automatic detection of multiple outliers in physiologic time series: notably temperature G. CORNELISSEN	157
The development of new statistical methods for event detection in time series R. POWNALL, K. GORDON, M. S. KNAPP and A. F. M. SMITH	161
Cortisol marker rhythmometry in pediatrics and clinical pharmacology E. HAEN, F. HALBERG and G. CORNELISSEN	165
Circadian and ultradian rhythm period alterations in apparently healthy subjects with and without placebo A. BICAKOVA-ROCHER, A. GORCEIX and A. NICOLAI	169
A chronopharmacological model of psychotropic drug action and its practical incidence on phases I and II methodology J. DOUCHAMPS, J. L. GUISET, J. P. BINON, J. M. BARRE, B. GHISTE and P. TUBELLO	173
An experimental design for evaluating treatment effects and circadian rhythm in respiratory function R. B. HARRIST, M. H. SMOLENSKY and P. H. SCOTT	177

Rhythmometry analysis on personal computers for applications to chronopharmacology studies B. P. HSI	181
Microprocessor-based ambulatory temperature and activity recorder J. NOUGUIER-SOULÉ and J. NOUGUIER	183
Diurnal variation in glucose levels can impede single rate continuous intravenous insulin therapy E. P. CHUTE, T. D. ROHDE, W. M. RUPP, F. J. GOLDENBERG, W. J. M. HRUSHESKY and H. BUCHWALD	185
A new technique to study the effect of dynamic administration of biochemical agents <i>in vitro</i> and <i>in vivo</i> M. L. GRUENBERG and J. J. PELUSO	189
Implantable and extracorporeal programmable drug delivery systems: what to program B. J. KENNEDY, D. COVELL and W. J. M. HRUSHESKY	193
A phase I trial of an implanted lithium battery-powered drug administration device system (DADS, Medtronic, inc.) for continuous doxorubicin infusion (CDI) N. J. VOGELZANG	197
Microcomputer-related modules for experimental standardization and temperature-activity-rhythmometry in pharmacology, toxicology and biology E. HALBERG, B. BROCKWAY, D. OSGOOD, W. NELSON, J. HALBERG, S. SANCHEZ De La PENA and F. HALBERG	201
 Section 5 — Endocrinology & Reproduction	
<i>Chairmen:</i> I. ASSENMACHER (Montpellier, France) Y. TOUITOU (Paris, France)	
Regulation and drug effect on the light-dependent circadian prolactin rhythms in estrogen primed female rats R. DOROW, H. WACHTEL, K. J. RETTIG, S. HASAN and R. HOROWSKI	205
Pineal rhythms: modification by drugs and light R. J. REITER	207

- The use of two different lighting regimens allows the dissociation of the mechanisms responsible for the action of melatonin on estrous cycles and those provoking the proestrous surge of gonadotropins 211
 R. W. RIVEST, U. LANG, M. L. AUBERT,
 M. F. NAWRATIL, A. SCHERRER and P. C. SIZONENKO
- Apparent absence of influence of melatonin on the circadian rhythm in cell division 215
 N. H. RUBIN, R. J. REITER and J. A. HOKANSON
- Circadian rhythm in cAMP content and in the activities of basal adenylate cyclase and phosphodiesterase in rat heart ventricles 219
 P.-H. LANG, H. BISSINGER and B. LEMMER
- Circannual peak-shift in circadian rhythm in basal cAMP content in rat heart ventricles 223
 B. LEMMER, P.-H. LANG and H. BISSINGER
- Interference with circadian rhythms of hemopoiesis by a synthetic hemoregulatory peptide 227
 O. D. LAERUM and W. R. PAUKOVITS
- Seasonal variations in the humoral immune response in mice following administration of thymic hormones 231
 M. DOUCET-JABOEUF, A. PELEGRIN, M. C. COT,
 J. GUILLEMAIN and M. BASTIDE
- Circadian dependent effect of epidermal growth factor, insulin and glucagon on hepatic pyruvate kinase and malic enzyme of mice 235
 R. J. FEUERS, R. R. DELONGCHAMP, L. A. SCHEVING,
 T. H. TSAI, D. A. CASCIANO, J. E. PAULY
 and L. E. SCHEVING
- Responses of nymphs of the large milkweed bug and pupae of the yellow mealworm to three compounds affecting insect growth 239
 R. E. REDFERN, D. K. HAYES, J. D. WARTHEN, JR.,
 A. B. DeMILO and T. P. McGOVERN
- Loss of circadian rhythmicity in plasma testosterone levels in adult men with Cushing's syndrome or under long-term treatment with glucocorticoids 243
 A. ANGELI, G. BELLOTTI, C. DE MICHELI, G. GATTI,
 R. CAVALLO, V. GALLO and F. AGRIMONTI

- Circadian patterns of cortisol and aldosterone in plasma, urine and peritoneal fluid of chronic uremic patients under continuous ambulatory peritoneal dialysis 247
 F. AGRIMONTI, G. TRIOLO, M. SALOMONE, D. BISBOCCI, G. PINNA, C. MARINONE and A. ANGELI

- Circadian-effect of somatostatin, glucagon, insulin, epidermal growth factor, pentagastrin and ACTH 1-17 on cell proliferation in mice 251
 L. E. SCHEVING, T. H. TSAI, L. A. SCHEVING and J. E. PAULY

Section 6 — Metabolism & Nutrition

Chairmen: H. NAKAGAWA (Osaka, Japan)
 A. ANGELI (Torino, Italy)

- Circadian rhythms of food intake and protein selection in young and old rats 255
 P. D. LEATHWOOD and L. ARIMANANA

- Chronopharmacological studies on central regulation of blood sugar homeostasis 259
 H. NAKAGAWA, K. NAGAI, T. MORI and H. YAMAMOTO

- Role of feeding schedule and pharmacokinetics in chronopharmacology of drugs acting on the central nervous system 263
 S. NAKANO, K. NAGAI and N. OGAWA

- Circadian and circanidian variations of the active calcium absorption: effects of dietary and environmental changes 267
 D. PANSU, C. ROCHE, C. BELLATON, M. MECHKOURI and TH. TEUVENY

- Cosinor and spectral analysis of circannual rhythms of mucous, acid and peptic gastric secretions in cats 271
 D. PANSU, M. VAGNE, M. COLLINET, A. DESVIGNE, A. REINBERG and M. MECHKOURI

- Circadian variations of plasma histamine and circulating leucocyte subtypes in magnesium deprived rats 275
 M. BENNACEUR, O. FERMENT, B. LEBEL and F. GAUDIN-HARDING

- Ultradian, circadian and circannual rhythms of blood glucose and injected insulin documented in self-controlled diabetics 279
 M. KOLLOP, A. BICAKOVA-ROCHER, P. DROUIN, L. MÉJEAN and G. DEBRY

Correlation between circadian-stage dependent variations of oral glucose tolerance test and alimentary patterns in young subjects with diabetic family history	283
P. MARRINO, G. RAVAGLIA, M. CAPELLI, S. E. COGLIANDRO, F. AGRIMONTI, D. FORNARO and A. LODI	
Circadian and ultradian rhythms in acute respiratory failure: effects of both continuous enteral feeding and ranitidine (H ₂ receptor blocker) infusion at constant rate	287
J. P. ACCARY, D. RIGAUD, J. CHASTRE, F. CANTOWITZ, C. GIBERT and S. BONFILS	
Postoperative enteral feeding patterns and diurnal temperature rhythms	291
I. T. CAMPBELL, R. P. MORTON and P. M. STELL	
Clinical study of cyclic (nocturnal) total parenteral and continuous enteral nutrition (including lipids) on circadian rhythms in serum lipids, lipoproteins, apolipoproteins and glucose	295
J. FABRE, O. GUILLARD, D. REISS and C. MATUCHANSKY	
Observations on the pharmacokinetics of ethanol	297
D. LAKATUA, T. S. LESAR, D. E. ZASKE, W. A. WARGIN and E. HAUS	
Circadian rhythms of insuline and HGH secretion in healthy and diabetic children	301
A. MROZIKIEWICZ and D. KIELCZEWSKA-MROZIKIEWICZ	
Increased stomach size and mortality observed in <i>ad libitum</i> fed CD2F ₁ adult male mice injected with insulin, glucagon, epidermal growth factor, saliva, or sympathometic submandibular gland stimulation	305
L. A. SCHEVING, T. H. TSAI, L. E. SCHEVING and J. E. PAULY	
Section 7 — Cardiovascular and Antiinflammatory Agents	
<i>Chairmen:</i> B. LEMMER (Frankfurt/M., West Germany G. LABRECQUE (Quebec, Canada)	
Biological rhythm studies on the hypotensive action of prostaglandin E ₂ and arachidonic acid in the rat	309
F. DORÉ, G. LABRECQUE, C. D'AUTEUIL and P. M. BÉLANGER	

Chronopharmacological studies of diuretics in hypertensive rats	313
F. DORÉ, C. D'AUTEUIL, G. LABRECQUE and P. M. BÉLANGER	
Chronopharmacokinetics of the beta-adrenoceptor-blocking drugs propranolol, metoprolol, sotalol and atenolol in plasma and organs after single and multiple dosing in the rat	317
B. LEMMER, H. WINKLER, M. FINK and T. OHM	
Circadian-stage-dependency in antagonist binding of ³ H-dihydroalprenolol to rat heart ventricular membranes	321
B. LEMMER and P.-H. LANG	
The Sine-O-Graph pulse monitor: a potential quantifier of cardiovascular wellness	325
W. J. M. HRUSHESKY	
Circatrigintan and circannual angina crises and isosorbide dinitrate compliance rhythms	329
R. W. MORRIS	
Circadian rhythm studies on BCG-induced migration of PMN in normal and adrenalectomized mice	333
J. P. BUREAU, L. GARRELLY, M. COUPÉ and G. LABRECQUE	
Circannual rhythms of PMN migration induced by BCG in intact mice	337
J. P. BUREAU, M. COUPÉ, L. GARRELLY and G. LABRECQUE	
Chronopharmacokinetic study of indomethacin	341
G. CUISINAUD, P. GUISSOU and J. SASSARD	
Chronotherapy of osteoarthritic patients: optimization of indomethacin sustained release (ISR)	345
F. LÉVI, C. Le LOUARN and A. REINBERG	
Chronobiological considerations of aspirin and indomethacin	349
L. PÖLLMANN	
Ketoprofen chronokinetics in human volunteers	353
P. QUENEAU, M. OLLAGNIER, H. DECOUSUS, Y. CHERRAH and B. PERPOINT	
Preliminary observations from a double blind crossover study to evaluate the efficacy of flurbiprofen given at different times of day in the treatment of rheumatoid arthritis	357
V. REJHOLEC, V. VITULOVA and J. VACHTENHEIM	

- Circadian and about-7-day (circaseptan) cardiovascular variation under treatment with the β -adrenergic blocker penbutolol 361
 F. HALBERG, E. HALBERG, F. CARANDENTE and E. HAUS

Section 8 — (A) Toxicology and (B) Aspects of Chronotherapeutics

Chairmen: M. KNAPP (Nottingham, England)
 I. ASHKENAZI (Tel Aviv, Israel)

- Chronotherapeutics — the importance of the individual and the need for an individual approach in therapeutic trials and in therapy 365
 M. S. KNAPP
- Chronobioassay of radiation injury in mice with and without time shift 369
 B. J. ARBOGAST and A. L. GERBES
- Influence of time of exposure to carbon tetrachloride on toxic liver injury 373
 J. V. BRUCKNER, R. LUTHRA, G. M. KYLE,
 S. MURALIDHARA, R. RAMANATHAN and D. ACOSTA
- Time dependent mercuric chloride induced acute renal failure in rats and mice 377
 J. C. CAL and J. CAMBAR
- Circadian variations in the acute toxicity of three aminoglycosides: gentamicin, dibekacin and netilmicin in mice 381
 C. PARIAT, J. CAMBAR and PH. COURTOIS
- Effects of circadian rhythm on kanamycin induced hearing loss 385
 J. FISCH, A. YONOVITZ and M. SMOLENSKY
- Murine circadian variations in susceptibility to 4¹-demethyl-epipodophyllotoxin- β -D-ethylidene glucoside (VP 16-213) as well as to the solvent alone in which it was suspended 389
 T. H. TSAI and L. E. SCHEVING
- Circadian variations in the response to hypoxia studies in animals and man 393
 C. HECKMANN and A. HARIRI

Time-related effects of hazardous factors (hypoxia, hyperbarism, etc.) on circadian rhythms of a set of physiologic variables in healthy young males	397
I. E. ASHKENAZI, J. RYBAK and C. HAREL	
Influence of sodium mineral waters on the circadian variation of urine excretions	399
CHR. GUTENBRUNNER, K. F. HOLTZ, B. MÜLLER and M. PETRI	
Chronobiological aspects of physical cure treatment	403
G. HILDEBRANDT	
Chronobiological approach to the treatment of cluster headache by lithium carbonate	407
E. FERRARI, P. A. BOSSOLO, G. BONO, G. MICIELI, A. VAILATI, L. MAGNANI, E. MARTIGNONI and G. NAPPI	
Circadian and circaseptan aspects of malarial infection and cyclosporine treatment in mice	411
S. SANCHEZ DE LA PENA, P. WOOD, E. HALBERG, G. CORNELISSEN, J. EATON and F. HALBERG	
Author Index	415
Subject Index	419

CIRCADIAN DYSRHYTHMIA IN THE BEHAVIOR OF EPILEPTIC CHILDREN WITH CLONAZEPAM AND/OR PHENOBARBITAL TREATMENT

M. Hallek,*** B. Arbogast,* T. Hellbrügge,* R. Schmid,* H. Arbogast*
and B. Kleiser*

*Institute für Soziale Pädiatrie, Universität München, F.R.G.

**ER. No 105 de Chronobiologie Humaine du CNRS, Fondation A. de
Rothschild, Paris, France

ABSTRACT

To evaluate the influence of anticonvulsants (clonazepam and phenobarbital) on behavior rhythms of children, fifteen 24-hr-observations with 1 observation unit per minute of the behavior of 3 healthy children without treatment and 12 epileptic children with phenobarbital and/or clonazepam treatment were performed on standardized hospital terms for several behavior parameters. The results demonstrate that clonazepam might cause grave circadian dysrhythmias, whereas phenobarbital does not alter circadian behavior rhythms to the same extent.

KEYWORDS

Petit mal epilepsy, children, behavior, clonazepam, phenobarbital, circadian dysrhythmia.

INTRODUCTION

In clinical practice, alterations of the sleep-waking cycle (drowsiness) or of other behavior components are quite often observed side effects of anticonvulsive medication. Nevertheless, some authors (Chemburkar, 1976) suggested that anticonvulsive effects of these drugs should be considered isolatedly from sedative side effects, the side effects disappearing after a while of drug administration. Therefore, the present study is an attempt to quantify the often fatal side effects in the behavior of long-term treated epileptic children by systematic clinical 24-hr observations.

METHODS

Subjects: Three groups of children with infantile spasms (a petit mal epilepsy) were studied. All epileptic children received anticonvulsivants in non-toxic plasmatic ranges. The first group C consisted of 3 patients who were treated by clonazepam only (mean age \pm S.E.M. 14 ± 4.6 months, 2 female (f) 1 male (m)), the second group PC consisted of 6 patients who

got a combination of phenobarbital and clonazepam (mean age of 13.3 ± 1.8 months, 4 f, 2 m) and the third group P consisted of 3 children who received phenobarbital only (mean age of 14.7 ± 6.1 months, 1 f, 2 m). A control group (Co) of 3 healthy subjects did not receive any treatment.

Procedures: All children were observed with observation unites of 1 min. by a trained team of four persons on standardized hospital terms within a 24-hr time span for 30 behavior parameters defined precisely beforehand. Only seven parameters (with highest incidence) were analysed by statistical methods: Incidence of sleep, restlessness, ocular seizures, epileptic seizures, weeping/crying, singing or similar sounds, arm movements. Nearly all children got medication regularly every 8 hrs (at 0700, 1500, 2200), and there was no difference to be found in children with irregular and regular medication scheme, whose results were therefore combined. Food intake hours (at 0700-0730, 1130-1200, 1600-1630) were also taken into account, but don't seem to influence the results. Plasmatic drug levels were controlled at 10.00 a. m. on the first day of the 24-hr observation. A continuous plasma drug level monitoring was impossible for technical and ethical reasons.

Analyses and calculations: Hourly data were analysed by the single cosinor method with trial periods (τ) = 24, 12, 8, 6 and 4 hrs for each parameter, each patient and each group. Basing on these results, the rhythm detection rate was calculated for the respective groups and periods by dividing the number (n) of rhythm detections to be found by the cosinor (with $p < 0.05$) by the total of the theoretically possible detections (all investigated parameters (i) · members of the group (m)):

$$\frac{n}{i \cdot m}$$

The rhythm detection values (in %) were compared by the χ^2 -test for evaluating a statistically significant difference among the four groups.

RESULTS

Figures 1 - 4 show the raw data and best fitting cosinor curve for the sleep incidence of the 3 treated groups and the control group. The control group shows a higher amplitude than all groups with anticonvulsive treatment and only a circadian sleep rhythm, whereas the groups C, PC and P exhibit ultradian sleep rhythms of which the 8-hr period in the group PC has to be considered as anormal in this age (Hellbrügge, 1964). Concerning the amplitude, no larger difference can be seen among the single treatment groups.

In figure 5 the rhythm detection rate resumes the results in an instructive manner: While phenobarbital results are hardly different from the control group, the groups PC and C (with combined or single clonazepam treatment) show that the circadian component of the behavior (7 parameters!) has mostly (PC) or totally (C) disappeared and that pathological 8-hr rhythms are persisting despite of the age of more than 1 year (group PC) or have even become predominant (group C). It is also impressively demonstrated (control group) that ultradian rhythms should normally have been disappeared in this age








Fig. 1-4. Sleep incidence. Raw data and best fitting cosinor curves. Control group ($p < 0.000$ for $\tau = 24$ h), group P ($p < 0.01/0.05$ for $\tau = 24/12$ h), group C ($p < 0.05/0.000$ for $\tau = 24/12$ h), group PC ($p < 0.000/0.05/0.01$ for $\tau = 24/12/8$ h).



Clonazepam and/or phenobarbital treatment

Fig. 5. Rhythm detection rate in %.

χ^2 -test: period (τ)	d. f.	p
24 (h)	3	< .1
12 (h)	3	< .025
8 (h)	3	< .1



range (with the exception of small 12-hr rudiments to admit).

DISCUSSION

Previous studies by Hellbrügge (1963, 1974), Parmelee (1961) and others showed that physiological and behavioral parameters gradually become circadian rhythmic after a few days (electric skin resistance in the first week, Hellbrügge 1963). Thus, the sleep-waking cycle normally gets a circadian organisation at the age of 1 - 7 months.

In this study we found circadian dysrhythmias in children with infantile spasms treated by anticonvulsants which could be due to 1. the epileptic disease or the often associated cerebral disorder, or 2. the anticonvulsive medication. The first hypothesis cannot totally be rejected, but does not seem probable because of the differences we found among the phenobarbital and the clonazepam groups. Therefore we suggest that clonazepam is able to cause grave circadian dysrhythmias and anormal 8-hr rhythms in the behavior of children. Phenobarbital, however, seems to be an anticonvulsive drug which does not influence circadian rhythms of the behavior and the sleep-waking cycle.

Further studies with a larger number of patients are suggested to establish a reasonable chronotherapy with anticonvulsive drugs and above all clonazepam. In this way, the fatal side effects which often augment the social and mental isolation of these patients already handicapped by their disease, could be diminished (together with an eventually augmented efficacy of anticonvulsants).

REFERENCES

- Chemburkar, J. (1976). The sleeping pattern and incidence of seizure discharges during whole night sleep in grand mal epileptics. *Neurol. Ind.*, 14 (3), pp. 141 - 147.
- Hallek, M., Reinberg, A. et al. (1983). Circadian and ultradian rhythms in behavior and seizures in children with petit mal epilepsy. *Chronobiologia*, 10, p. 131.
- Hellbrügge, T., Lange, J. et al. (1963). Über das Entstehen einer 24-Stunden-Periodik physiologischer Funktionen im Säuglingsalter. *Fortschr. Med.* 81, 19.
- Hellbrügge, T. (1974). The development of circadian and ultradian rhythms of premature and full-term infants. In: L.E. Scheving, F. Halberg et al. (Eds.), *Chronobiology*, pp. 339 - 341.
- Janz, D. (1974). Epilepsy and the sleep-waking cycle. In: P. J. Vinken and G.W. Bruyn (Eds), *Handbook of Clinical Neurology*, Vol. 15, The Epilepsy, Amsterdam, pp. 457 - 490.
- Parmelee, A.H. (1961). A study of one infant from birth to 8 month of age. *Act. paed. scand.* 50, pp. 160 - 170.